Short Interest in Vigil Neuroscience, Inc. (NASDAQ:VIGL) Increases By 51.3%

Vigil Neuroscience, Inc. (NASDAQ:VIGL) was the target of a significant increase in short interest in November. As of November 15th, there was short interest totalling 736,700 shares, an increase of 51.3% from the October 31st total of 487,000 shares. Approximately 3.9% of the company’s stock are short sold. Based on an average trading volume of 112,200 shares, the short-interest ratio is currently 6.6 days.

Vigil Neuroscience Stock Up 7.4 %

VIGL stock traded up $0.17 during trading on Friday, reaching $2.47. The stock had a trading volume of 336,264 shares, compared to its average volume of 236,055. Vigil Neuroscience has a one year low of $2.08 and a one year high of $6.06. The company’s 50 day moving average is $3.42 and its two-hundred day moving average is $3.64. The company has a market capitalization of $100.97 million, a price-to-earnings ratio of -1.16 and a beta of 1.92.

Institutional Trading of Vigil Neuroscience

A number of hedge funds have recently bought and sold shares of the business. Ensign Peak Advisors Inc grew its stake in Vigil Neuroscience by 72.8% in the 2nd quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company’s stock valued at $1,580,000 after purchasing an additional 166,442 shares during the period. abrdn plc bought a new stake in shares of Vigil Neuroscience during the 3rd quarter worth $799,000. Point72 Asset Management L.P. bought a new position in Vigil Neuroscience during the second quarter valued at about $5,940,000. Vanguard Group Inc. increased its holdings in Vigil Neuroscience by 11.9% during the first quarter. Vanguard Group Inc. now owns 894,473 shares of the company’s stock worth $3,050,000 after buying an additional 95,276 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Vigil Neuroscience in the second quarter worth about $87,000. 83.64% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Guggenheim lowered their target price on Vigil Neuroscience from $17.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, August 14th. JMP Securities reiterated a “market outperform” rating and set a $22.00 price objective on shares of Vigil Neuroscience in a report on Tuesday. HC Wainwright restated a “buy” rating and issued a $17.00 target price on shares of Vigil Neuroscience in a report on Friday, November 8th. Finally, Wedbush lifted their price target on Vigil Neuroscience from $23.00 to $24.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Vigil Neuroscience currently has a consensus rating of “Moderate Buy” and an average price target of $16.60.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.